Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 23(3)2022 Jan 22.
Article in English | MEDLINE | ID: mdl-35163148

ABSTRACT

Increased soluble endoglin (sENG) has been observed in human brain arteriovenous malformations (bAVMs). In addition, the overexpression of sENG in concurrence with vascular endothelial growth factor (VEGF)-A has been shown to induce dysplastic vessel formation in mouse brains. However, the underlying mechanism of sENG-induced vascular malformations is not clear. The evidence suggests the role of sENG as a pro-inflammatory modulator, and increased microglial accumulation and inflammation have been observed in bAVMs. Therefore, we hypothesized that microglia mediate sENG-induced inflammation and endothelial cell (EC) dysfunction in bAVMs. In this study, we confirmed that the presence of sENG along with VEGF-A overexpression induced dysplastic vessel formation. Remarkably, we observed increased microglial activation around dysplastic vessels with the expression of NLRP3, an inflammasome marker. We found that sENG increased the gene expression of VEGF-A, pro-inflammatory cytokines/inflammasome mediators (TNF-α, IL-6, NLRP3, ASC, Caspase-1, and IL-1ß), and proteolytic enzyme (MMP-9) in BV2 microglia. The conditioned media from sENG-treated BV2 (BV2-sENG-CM) significantly increased levels of angiogenic factors (Notch-1 and TGFß) and pERK1/2 in ECs but it decreased the level of IL-17RD, an anti-angiogenic mediator. Finally, the BV2-sENG-CM significantly increased EC migration and tube formation. Together, our study demonstrates that sENG provokes microglia to express angiogenic/inflammatory molecules which may be involved in EC dysfunction. Our study corroborates the contribution of microglia to the pathology of sENG-associated vascular malformations.


Subject(s)
Endoglin/administration & dosage , Endothelium, Vascular/pathology , Inflammation/pathology , Microglia/pathology , Neovascularization, Pathologic/pathology , Vascular Diseases/pathology , Vascular Endothelial Growth Factor A/administration & dosage , Animals , Endothelium, Vascular/immunology , Endothelium, Vascular/metabolism , Inflammation/chemically induced , Inflammation/immunology , Inflammation/metabolism , Male , Mice , Mice, Inbred C57BL , Microglia/drug effects , Microglia/immunology , Microglia/metabolism , Neovascularization, Pathologic/chemically induced , Neovascularization, Pathologic/immunology , Neovascularization, Pathologic/metabolism , Vascular Diseases/chemically induced , Vascular Diseases/immunology , Vascular Diseases/metabolism , Vascular Endothelial Growth Factor A/adverse effects
2.
Am J Reprod Immunol ; 76(4): 272-9, 2016 10.
Article in English | MEDLINE | ID: mdl-27476638

ABSTRACT

PROBLEM: Angiogenic imbalance during pregnancy is associated with immune activation, hypertension, increased T cell infiltration, and neurological insults. METHOD OF STUDY: On gestational day (GD) 12, timed-pregnant rats were infused with anti-angiogenic factors sFlt-1 and sEndoglin (4.7 and 7 µg/kg) to create HELLP syndrome via mini-osmotic pumps for 8 days, with a subset of these rats having Orencia (2 mg/kg) infused on GD13. On GD19, blood-brain barrier (BBB) permeability was evaluated via Evan's Blue infusion, blood was collected for T-cell measurements, inflammatory cytokine secretion. Brain tissues were also collected to examine inflammatory cytokine infiltration. RESULTS: T-cell attenuation with Orencia decreased circulating CD4(+) and CD8(+) T cells, circulating tumor necrosis factor alpha (TNFα) and IL-17, BBB permeability and significantly decreased biochemical evidence of HELLP compared to untreated HELLP rats. CONCLUSIONS: These data support the hypothesis that T cells have a critical role in contributing to the pathophysiology that is seen in angiogenic imbalance during pregnancy.


Subject(s)
Blood-Brain Barrier , HELLP Syndrome/immunology , Neovascularization, Pathologic , Pregnancy , T-Lymphocytes/immunology , Abatacept/therapeutic use , Angiogenesis Inhibitors/administration & dosage , Animals , Anti-Inflammatory Agents/therapeutic use , Capillary Permeability , Disease Models, Animal , Endoglin/administration & dosage , Female , HELLP Syndrome/drug therapy , Humans , Hypertension , Inflammation Mediators/metabolism , Interleukin-17/metabolism , Lymphocyte Activation , Rats , Rats, Sprague-Dawley , Tumor Necrosis Factor-alpha/metabolism , Vascular Endothelial Growth Factor Receptor-1/administration & dosage , Vascular Endothelial Growth Factor Receptor-1/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...